Latest Content

Darlifarnib plus Cabometyx showed tumor responses in resistant kidney cancer following prior treatment.

An expert discusses the need to tailor treatment duration in bladder cancer, balancing improved outcomes with toxicity and exploring new tools.

Tamera Anderson-Hanna reflects on survivorship, redefining life with family, travel, purpose and giving back while embracing time as a precious guide.

Patients with cancer have a new generic option for methotrexate injection following FDA approval of a therapeutic equivalent for multiple conditions.

The FDA accepted an investigational new drug application for chemo-related neuropathy, advancing a potential non-opioid treatment into a clinical trial.

The OPTIMAL trial finds oral DHP107 is as effective as IV paclitaxel for patients with advanced breast cancer while reducing side effects like neuropathy.

Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase 2 trial.

A 30-year study reveals one in six AYA cancer survivors develop a new primary neoplasm, with risks highest for breast and oral cancer survivors.

Before my daughter was diagnosed with breast cancer, the “M” word was not a part of my vocabulary.

After an aggressive breast cancer diagnosis, psychologist Loraine Alderman retires to bridge gaps in patient literature through powerful advocacy.

Dr. Sandy Srinivas explains how age, comorbidities and medications influence personalized prostate cancer treatment decisions.

Dr. W. Fraser Symmans explains how ctDNA is replacing CTCs to monitor breast cancer, detect mutations and track minimal residual disease

Meet Dr. Susan MacDonald, a urologist with stage 4 breast cancer who is the host of CURE's new vlog series, "Demystifying the Darkness."